Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edinrin Obasare

Clinical Cardiac Electrophysiology Auburn, NY Medical Doctor

NPI 1093027278 CMS profile 1077599

17 Lansing St, Auburn, NY 13021

Open in the dashboard

General payments

$94,373

873 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edinrin Obasare of Auburn, NY is reported in the CMS Open Payments database as having received $94,373 across 873 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,349 102
2024 General $7,396 59
2023 General $14,974 158
2022 General $21,599 180
2021 General $15,667 196
2020 General $8,534 94
2019 General $9,854 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edinrin Obasare
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Edinrin Obasare were reported at $16,349. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Edinrin Obasare Clinical Cardiac Electrophysiology median Middle half National median
2019 $9,854 $2,361 $585–$8,260 $163
2020 $8,534 $993 $247–$4,351 $114
2021 $15,667 $1,185 $326–$4,739 $132
2022 $21,599 $2,073 $554–$6,789 $149
2023 $14,974 $2,568 $759–$8,159 $160
2024 $7,396 $2,557 $703–$7,403 $164
2025 $16,349 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $33,854 213 payments
  2. Medtronic, Inc. $14,050 164 payments
  3. Boston Scientific Corporation $11,846 61 payments
  4. Abbott Laboratories $10,424 112 payments
  5. Medical Device Business Services, Inc. $8,550 58 payments
  6. Atricure, Inc. $3,774 24 payments
  7. Medtronic Vascular, Inc. $2,759 34 payments
  8. Biosense Webster, Inc. $2,605 49 payments
  9. Janssen Pharmaceuticals, Inc $1,741 42 payments
  10. AstraZeneca Pharmaceuticals LP $1,534 32 payments
  11. Other $3,237 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $47,084 129 payments
  2. Food and Beverage $46,964 742 payments
  3. Education $325 2 payments
Products named General payments · program years 2019–2025
  1. BioMonitor $14,774 82 payments
  2. Solia $14,033 67 payments
  3. Acticor 7 VR-T DX $9,305 36 payments
  4. Edora 8 DR-T $8,226 25 payments
  5. Rivacor $7,707 59 payments
  6. Edora $7,707 59 payments
  7. Acticor $7,707 59 payments
  8. Rivacor 7 DR-T $7,446 15 payments
  9. Carto 3 System $7,010 53 payments
  10. Carto 3 $3,942 43 payments
  11. Other $45,208 551 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

169

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$60,914

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

36.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 44 $40,537
Entresto Sacubitril/Valsartan Brand 17 $18,243
Flecainide Acetate Generic 16 $1,077
Metoprolol Succinate Generic 59 $588
Amiodarone Hcl Generic 14 $294
Carvedilol Generic 19 $176

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$55,639

Medicare's payments for the services billed

Medicare patients

571

Average age 79

Services billed

1,175

264 women, 307 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 58%
Ischemic heart disease 50%
Heart failure 49%
Arthritis 49%
Chronic kidney disease 34%
Diabetes 31%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

873 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record